Klisyri (Tirbanibulin)

Tirbanibulin, the active ingredient in Klisyri, is a Src kinase inhibitor presented as a 1% (w/w) topical solution for topical use. It treats actinic keratosis in adult patients. GNH USA supplies Klisyri as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Klisyri (tirbanibulin) is indicated for the treatment of actinic keratosis, a precancerous skin lesion caused by chronic ultraviolet exposure.

Actinic keratosis: reduces lesion size and number, helping to prevent progression to squamous cell carcinoma.

Klisyri may cause local skin reactions and, rarely, systemic hypersensitivity.

Common Side Effects: - Redness at the application site - Itching or mild pruritus - Dryness or flaking of treated skin - Burning sensation - Mild swelling or edema - Crusting or scaling

Serious or Rare Side Effects: - Severe allergic reaction (anaphylaxis) - Extensive skin ulceration - Contact dermatitis with blistering - Persistent erythema beyond the treatment area - Systemic hypersensitivity (e.g., fever, malaise)

Before using Klisyri, consider the following precautions: - Contraindication: known hypersensitivity to tirbanibulin or any excipients. - Avoid application on compromised skin or open wounds. - Do not use on mucous membranes or ocular surfaces. - Monitor for signs of severe local irritation or infection. - Pregnant or breastfeeding individuals should only use if the potential benefit justifies the potential risk. - Store at below 25°C: keep in the original container, protect from moisture and direct sunlight.

Klisyri has a limited interaction profile, but the following should be considered:

Major Interactions (Avoid): - Concurrent use with other topical keratolytic agents (e.g., salicylic acid) may increase irritation. - Application together with potent corticosteroids may mask local adverse reactions.

Moderate Interactions (Monitor Closely): - Use with systemic immunosuppressants could theoretically affect wound healing. - Co‑administration of photosensitising drugs may exacerbate sun‑related skin damage. - Over‑the‑counter acne or wart treatments applied to adjacent areas should be spaced to reduce cumulative irritation. - Patients using extensive UV‑light therapy should limit exposure during treatment.